Literature DB >> 30116960

Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).

Yeun-Yoon Kim1, Jin-Young Choi2, Claude B Sirlin3, Chansik An1, Myeong-Jin Kim1.   

Abstract

The 2017 Core of the computed tomography (CT)/magnetic resonance imaging (MRI) Liver Imaging Reporting and Data System (LI-RADS) provides clear definitions and concise explanations of the CT/MRI diagnostic algorithm. Nevertheless, there remain some practical and controversial issues that radiologists should be aware of when using the system. This article discusses pitfalls and problems which may be encountered when the version 2017 diagnostic algorithm is used for CT and MRI. The pitfalls include challenges in applying major features and assigning the LR-M category, as well as categorisation discrepancy between CT and MRI. The problems include imprecision of category codes, application of ancillary features, and regional practice variations in hepatocellular carcinoma (HCC) diagnosis. Potential solutions are presented along with these pitfalls and problems. KEY POINTS: • Although the diagnostic algorithm provides clear and detailed explanations, major feature evaluation can be subject to pitfalls and differentiation of HCC and non-HCC malignancy remains challenging. • Ancillary features are optional and equally weighted. However, features such as hepatobiliary phase hypointensity and restricted diffusion have greater impact on HCC diagnosis than other ancillary features and may merit greater emphasis or weighting. • LI-RADS was initially developed from a Western paradigm, which may limit its applicability in the East due to regional practice variations. In Eastern Asia, high sensitivity is prioritised over near-perfect specificity for HCC diagnosis in order to detect tumours at early stages.

Entities:  

Keywords:  Algorithms; Diagnosis; Liver cancer; Magnetic resonance imaging; Tomography

Mesh:

Year:  2018        PMID: 30116960     DOI: 10.1007/s00330-018-5641-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  38 in total

1.  Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI.

Authors:  Jordi Rimola; Alejandro Forner; Silvia Tremosini; Maria Reig; Ramón Vilana; Luis Bianchi; Carlos Rodríguez-Lope; Manel Solé; Carmen Ayuso; Jordi Bruix
Journal:  J Hepatol       Date:  2012-02-04       Impact factor: 25.083

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

3.  Liver Imaging Reporting and Data System:: Substantial Discordance Between CT and MR for Imaging Classification of Hepatic Nodules.

Authors:  Yu-Dong Zhang; Fei-Peng Zhu; Xun Xu; Qing Wang; Chen-Jiang Wu; Xi-Sheng Liu; Hai-Bin Shi
Journal:  Acad Radiol       Date:  2016-01-07       Impact factor: 3.173

4.  Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging.

Authors:  Matthew S Davenport; Shokoufeh Khalatbari; Peter S C Liu; Katherine E Maturen; Ravi K Kaza; Ashish P Wasnik; Mahmoud M Al-Hawary; Daniel I Glazer; Erica B Stein; Jeet Patel; Deepak K Somashekar; Benjamin L Viglianti; Hero K Hussain
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

5.  How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma.

Authors:  Keitaro Sofue; Claude B Sirlin; Brian C Allen; Rendon C Nelson; Carl L Berg; Mustafa R Bashir
Journal:  J Magn Reson Imaging       Date:  2015-11-11       Impact factor: 4.813

6.  Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.

Authors:  Anna Darnell; Alejandro Forner; Jordi Rimola; María Reig; Ángeles García-Criado; Carmen Ayuso; Jordi Bruix
Journal:  Radiology       Date:  2015-02-05       Impact factor: 11.105

7.  Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-03-14       Impact factor: 5.315

8.  Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation.

Authors:  J H Lee; J M Lee; S J Kim; J H Baek; S H Yun; K W Kim; J K Han; B I Choi
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

9.  Why does living donor liver transplantation flourish in Asia?

Authors:  Chao-Long Chen; Catherine S Kabiling; Allan M Concejero
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-08       Impact factor: 46.802

10.  Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma.

Authors:  Chansik An; Mi-Suk Park; Dowhan Kim; Yeo-Eun Kim; Woo-Suk Chung; Hyungjin Rhee; Myeong-Jin Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

View more
  5 in total

Review 1.  Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.

Authors:  Jae Hyun Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

2.  Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma.

Authors:  Hanyu Jiang; Xijiao Liu; Jie Chen; Yi Wei; Jeong Min Lee; Likun Cao; Yuanan Wu; Ting Duan; Xin Li; Ling Ma; Bin Song
Journal:  Cancer Imaging       Date:  2019-12-05       Impact factor: 3.909

3.  Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.

Authors:  Jae Hyon Park; Yong Eun Chung; Nieun Seo; Jin-Young Choi; Mi-Suk Park; Myeong-Jin Kim
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

4.  Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma.

Authors:  Yueming Li; Jianwei Chen; Shuping Weng; Chuan Yan; Rongping Ye; Yuemin Zhu; Liting Wen; Dairong Cao; Jinsheng Hong
Journal:  Ann Transl Med       Date:  2021-01

5.  Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis.

Authors:  Debra T Choi; Jessica A Davila; Shubhada Sansgiry; Eric David; Hardeep Singh; Hashem B El-Serag; Yvonne Hsiao-Fan Sada
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-18       Impact factor: 13.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.